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Practice points 25 
1. Level of access to MS Specialists by people with progressive MS in the UK was 26 
high at 95%. 27 
2. The most utilised practitioners by participants for their MS were MS specialist 28 
Doctor/Nurses, General Practitioners and Physiotherapists.  29 
3. Level of access to a regular clinical review was 74%, however, 37% received their 30 




Background: According to current UK guidelines everyone with progressive MS 33 
should have access to an MS Specialist but levels of access and use of clinical 34 
services is unknown. 35 
Objective: To investigate access to MS Specialists, use of clinical services and 36 
Disease Modifying Therapies (DMT) by people with progressive MS in the United 37 
Kingdom. 38 
Methods: A UK wide, online survey was conducted via the UK MS Register.  39 
Inclusion criteria: age over 18 years, primary or secondary progressive MS and a 40 
member of the UK MS Register.  Participants were asked about access to MS 41 
Specialists; recent clinical service use; receipt of regular review and current and 42 
previous DMT use.  Participant demographics; quality of life and disease impact 43 
measures were supplied from the UK MS Register. 44 
Results: In total 1298 participants responded: 5% were currently taking DMT; 23% 45 
had previously taken DMT; and 95% reported access to an MS Specialist.  Most 46 
utilised services were: MS Doctor/Nurse (50%), General Practitioner (45%), and 47 
Physiotherapist (40%). Seventy-four percent received a regular review although 37% 48 
received theirs less than annually.  Current DMT use was associated with better 49 
quality of life but past DMT use was associated with poorer quality of life and higher 50 
impact of disease.   51 
Conclusion: Access to, and use of, MS Specialists was high.  However a gap in 52 





Multiple Sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease 56 
of the central nervous system resulting in axonal and grey matter loss. It is estimated 57 
that there are 130,000 people living with MS in the United Kingdom (UK).1 At time of 58 
diagnosis, approximately 15% of people with MS are diagnosed with Primary 59 
Progressive MS (PPMS), 80% with Relapsing Remitting MS (RRMS) and 5% with 60 
Progressive Relapsing MS; and approximately 80% of those with RRMS will go on to 61 
develop Secondary Progressive MS (SPMS).2 62 
Disease Modifying Therapies (DMT) are currently available to those who have 63 
RRMS, or are still experiencing relapses in the early stages of SPMS. Disease 64 
modifying therapies have been found to delay the transition from RRMS to SPMS.3 65 
However, there are currently no effective licensed pharmacological treatments for 66 
slowing the progression of disability in both primary and secondary progressive MS, 67 
although Ocrelizumab has been shown to decrease disability progression by 25% in 68 
people with primary progressive MS.3  Due to the lack of available effective 69 
pharmacological treatments for disease activity in progressive MS, specialist 70 
rehabilitation services are of particular importance. Despite this, access to specialist 71 
services throughout the UK can be difficult, and people with progressive MS are 72 
often told that there is little available for them, and advised to self-manage their 73 
condition.4 The International Progressive MS Alliance have subsequently highlighted 74 
rehabilitation for people with progressive MS as a research priority,5 and disciplines 75 
such as physiotherapy have positive evidence in the rehabilitation of people with 76 
progressive MS.6  77 
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The current National Institute for Health and Care Excellence (NICE) guidelines for 78 
multiple sclerosis and Healthcare Improvement Scotland clinical standards for 79 
Neurological Health Services state that everyone with MS in the UK should have 80 
access to an MS Specialist and receive a comprehensive regular review at least 81 
annually, by a member of the multi-disciplinary MS team.7,8 This review should cover 82 
all aspects of care including medication; symptom management; disease course; 83 
general health; participation and social care needs and does not have to be 84 
conducted in a clinical environment. Recently, MS Specialist Nurses were found to 85 
be the most consulted health care professional9 and 86% of people with MS 86 
reportedly had access to a Neurologist or MS Nurse.10 However, these studies did 87 
not differentiate between MS types. In some areas within the UK, such as London 88 
and Northern Ireland, a limited MS service provision has been found.11,12 Furthermore 89 
in England and Wales 55% of patient comments regarding provision of NHS MS 90 
services were negative.13   91 
The purpose of this study was to investigate access to, and use of, clinical services 92 
for people with primary and secondary progressive of MS. Specifically exploring 93 
whether people with progressive MS had access to an MS Specialist; what clinical 94 
services they used; if they received an regular review; their current and previous use 95 
of DMT and to explore any associations between these variables and quality of life 96 
and physical and psychological impact of MS.   97 
 98 
Methods 99 
The UK MS Register is an online register funded by the MS Society. People with MS 100 
become members voluntarily, and answer both regular and online surveys.14 101 
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Members self-report their MS diagnosis type, demographical information and 102 
complete self-report outcome measures, such as the EQ-5D-3L Health 103 
Questionnaire (EQ-5D-3L) and the physical and psychological sub-scales of the 104 
Multiple Sclerosis Impact Scale-29 version 2 (MSIS-29) every three months. Data 105 
are anonymised using the Secure Anonymised Information Linkage system.15 At the 106 
time of this study there were 11,041 people on the UK MS Register with 4,384 107 
people active on the Register in the previous six months. 108 
Design and participant recruitment 109 
A cross-sectional survey design was used. The survey was available on the UK MS 110 
Register from August to October 2015. To be eligible for inclusion a participant had 111 
to be 18 years old or over, living in the UK, diagnosed with progressive MS and 112 
registered on the UK MS Register. Potential participants were identified by the UK 113 
MS Register, and emailed informing them of the survey. The survey was accessed 114 
only via the UK MS Register, and completion was regarded as informed consent. 115 
Ethical approval was obtained from the College of Medical, Veterinary & Life 116 
Sciences Ethics Committee, University of Glasgow and the study underwent peer 117 
review by the information governance panel of the UK MS Register (South West - 118 
Central Bristol Research Ethics Committee, Ref: 11/SW/0160). 119 
The survey was in two sections.  The first asked about access to, experiences and 120 
opinion of physiotherapy services and complementary therapies in the UK, and has 121 
been described elsewhere.16 The second section asked if a participant had access to 122 
an MS Specialist: defined as a clinician with MS Specialist skills.  Participants were 123 
also asked which clinicians they used in the previous three months for their MS. 124 
Participants were asked if they received a regular review for their MS; how often that 125 
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review took place; who normally undertook the review; and where the review 126 
normally took place. Finally, previous and current use of DMT was explored and 127 
participants were asked to select whether they were currently taking, or had 128 
previously taken, any of the following: Beta-interferon (Rebif, Avonex, Betaferon), 129 
Glatiramer acetate (Copaxone), Dimethyl fumarate (Tecfidera), Teriflunomide 130 
(Aubagio), Natalizumab (Tysabri, Antigren), Fingolimod (Gilenya, Novartis), 131 
Mitoxantrone (novantrone), and Alemtuzumab (Lemtrada). A copy of the survey is 132 
available on request. Due to the structural progression of the survey not all 133 
participants answered all questions.  134 
Access 135 
This study explored two components of access: the opportunity to enter into the 136 
service (regardless of organisational barriers such as waiting times and distance to 137 
travel) and the utilisation of services.17  In this survey these two terms were referred 138 
to as ‘access’ and ‘use’ respectively.  Whilst these terms were not explicitly 139 
explained the meaning was implied by questions asked, for example “Which of the 140 
following clinicians could you see if you wanted to?” implied the availability of the 141 
opportunity to see a clinician and “Which of the following clinicians have you seen in 142 
the past three months for your MS?” implied the utilisation of services.  Barriers to 143 
accessing physiotherapy were explored in some detail and have been published 144 
elsewhere.16 145 
Access to an MS Specialist 146 
Participants were asked if they had access to an MS Specialist service.  If they 147 
answered ‘yes’ they were then asked which clinicians they had seen recently for their 148 
MS.  If they answered ‘no’ they were then asked which clinicians they could see if 149 
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they wanted to.  Included in this list were ‘MS Specialist Nurse’ and ‘MS Specialist 150 
Doctor/ Neurologist’.  The answers of those who reported having access to an MS 151 
Specialist service and of those who reported they could see an MS Specialist Nurse 152 
or Doctor were combined.  This gave the total level of access to MS Specialists of 153 
this cohort.   154 
Additional data from UK MS Register   155 
In addition to data collected from the survey, the following data routinely collected by 156 
the UK MS Register were accessed: type of MS; age; gender; time since diagnosis 157 
of MS; quality of life measured by the EQ-5D-3L; the physical and psychological sub-158 
scales of the MSIS-29; Lower Super Output Area codes [England and Wales] and 159 
Output Area codes [Scotland] (there were no available geographical data for 160 
participants from Northern Ireland). Lower Super Output Area codes and Output 161 
Area codes, which are used to tabulate census and statistical data by the Office of 162 
National Statistics, were combined with data available from the Office for National 163 
Statistics and the Scottish Office for National Statistics18,19 to generate the following: 164 
rural or urban dwelling, and Strategic Health Authority for participants in England (in 165 
2013 NHS England divided England into ten regions called Strategic Health 166 
Authorities each of which contained multiple NHS trusts). Rural dwelling was defined 167 
as a settlement with a population of 10,000 or less.20  168 
The EQ-5D-3L is a self-report measure of quality of life generating an index ranging 169 
from -1 to 1, a higher index indicating a better quality of life.21 The MSIS-29 is a 29-170 
item self-report measure with physical and psychological sub-scales to measure the 171 
impact of MS.22 The physical sub-scale ranges from 20-80 and the psychological 172 
sub-scale ranges from 9-36.  A lower score indicates a lower impact of MS.   173 
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Data analysis 174 
Data were analysed using IBM SPSS v22. Descriptive statistics were used to 175 
characterise demographic data and all outcome variables. The responses to 176 
individual questions are presented as percentages. Data were tested for normality 177 
and due to non-normal distribution Chi-square and Mann-Whitney tests were used 178 
as appropriate.  A significance level of p<0.05 was used.   179 
 180 
Results 181 
In total 2,538 registrants with progressive MS were emailed by the UK MS register, 182 
and 1,298 participants completed the survey generating a 51% response rate; 183 
England (n=1,030), Scotland (n=130), Wales (n=104) and Northern Ireland (n=21). 184 
Participants had a mean age of 59 (SD 8) years and time since diagnosis of 16 (SD 185 
9) years; the female to male ratio was 1.7: 1; 37% had PPMS (n=486) and 63% had 186 
SPMS (n=812). Mean EQ-5D-3L index was 0.49 ± SD 0.2, indicating a poorer quality 187 
of life compared to general population of the same age who would have an 188 
approximate index of 0.8.23  The mean MSIS-29 physical and psychological sub-189 
scores were 55.97 (SD 12.64) and 19.96 (SD 6.10) respectively indicating that this 190 
sample was moderately affected both physically and psychologically by their MS 191 
(Table 1).  Compared to those with SPMS, people with  PPMS were younger, had a 192 
shorter time since diagnosis, had a higher EQ-5D-3L index and lower psychological 193 
and physical scores on the MSIS-29 (all p<0.005).   194 
In total 95% (n=1,184) of participants reported that they had access to an MS 195 
Specialist, and 96% (n=959) of those who had access reported they would be able to 196 
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access the specialist if their symptoms or needs changed. Figure 1 shows access to 197 
MS Specialists across the UK.  Access to an MS Specialist ranged from 92% in 198 
Yorkshire and the Humber and the East Midlands to 98% in Wales.   199 
Overall, 81% (n=1046) of participants reported using clinical services for their MS in 200 
the previous three months. The most commonly used clinical services were MS 201 
Specialist Doctor/Nurse (50%, n=517), General Practitioner (45%, n=467), and 202 
Physiotherapist (40%, n=414) (Figure 2). Of the participants receiving clinical 203 
services for their MS: 46% (n=481) were receiving a single service and 54% (n=565) 204 
were receiving more than one service.  From those who answered the question 20% 205 
(n=88) of participants reported they were currently taking DMT (PPMS n=18, SPMS 206 
n=70), and 24% (n=303) reported that they had previously taken DMT (PPMS n=37, 207 
SPMS n=266).  These numbers equated to 5% and 23% of the total sample 208 
respectively.   209 
In total, 74% (n=917) of participants received a regular review; 56% (n=505) 210 
received that review annually; 63% (n=569) had their review performed by an MS 211 
Specialist Doctor and 27% (n=248) reported it was performed by a nurse. A total of 212 
90% (n=819) reported usually receiving their review in a hospital or clinic (Table 2).  213 
Ninety percent of participants who were currently taking a DMT received a regular 214 
review: 6% received their review twice a year, 51% once a year, 41% less frequently 215 
than once a year and 2% did not know (not shown in tables). 216 
There was a statistically significant association between access to an MS Specialist 217 
and receiving a regular review (p<0.001) (Table 3).  Access to an MS Specialist was 218 




Participants who were in receipt of a single clinical service, as opposed to multiple 221 
services, for their MS had a better quality of life as measured by the EQ-5D-3L index 222 
(p<0.001), and less of a physical and psychological impact of MS as measured by 223 
the MSIS-29 (p<0.001).  Use of single or multiple services was, however, not 224 
dependent on MS type (n=1045, p=0.165) or whether a participant lived in a rural or 225 
urban location (n=1003, p=0.972) (not shown in tables).  Participants who were 226 
currently taking DMT for their MS had a better quality of life (p=0.016) than those 227 
who were not taking DMT.   Those who had previously taken DMT, however, had a 228 
poorer quality of life (p<0.001), and greater physical (p<0.001) and psychological 229 
(p=0.006) impact than those who had not taken DMTs (Table 4).  There were no 230 
differences in quality of life and disease impact scores between those who did and 231 
did not have access to an MS Specialist or access to a review and there was no 232 
difference in the psychological or physical impact of MS between those who were 233 
and were not currently taking DMT (Table 4). 234 
 235 
Discussion 236 
This study had the largest sample solely of people with progressive MS to be 237 
surveyed to date, and was the first to investigate access to, and use of clinical 238 
services for people with progressive forms of MS across the UK.   239 
In this sample of 1298, access to an MS Specialist was high (95%) and was similar 240 
across the UK (Figure 1). This was slightly higher than the outcome of a survey 241 
carried by the MS Society in people with all types of MS in the UK which reported 242 
86% of participants had access to a Neurologist or MS Nurse.10 A previous study 243 
conducted in London reported a lack of access to MS related services amongst 244 
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those severely affected by MS11 however the present study indicates that 95% of 245 
people with progressive MS have access to an MS Specialist. This difference in 246 
results may indicate improvements in service provision, since Edmonds et al.11 247 
carried out their study and that the people in this sample were not severely affected 248 
by their MS. Interestingly there were no differences in quality of life and disease 249 
impact measures between those who did and those who did not have access to an 250 
MS Specialist.  However, there were only a relatively small number of people who 251 
did not have access in these analyses so results should be interpreted with caution. 252 
While access to MS Specialists was high not all received a regular review, as is 253 
recommended by current guidelines and standards.7,8 Just under three quarters of 254 
participants received a regular review and 37% of these received their review less 255 
frequently than annually. This is a breach of the National Institute for Healthcare and 256 
Excellence guidelines and the Healthcare Improvement for Scotland clinical 257 
standards. With the potential advent of pharmacological treatments for PPMS 258 
disease activity 3 a regular clinical review will in the future be particularly important in 259 
the care of people with progressive MS.  Indeed of those who were currently 260 
receiving a DMT 90% were in receipt of a regular review but only 57% received that 261 
review once a year or more frequently.  However, it should be noted that there were 262 
no differences in quality of life or disease impact measures between those who did 263 
and did not receive a regular review.   264 
Use of clinical services in this study’s participants was high. The three most utilised 265 
clinical services were, MS Specialist Nurse or Doctor, General Practitioner, and 266 
Physiotherapist (Figure 2). This finding was similar to two previous studies surveying 267 
people with all types of MS in the UK and in Europe.9,24 This may indicate that 268 
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people with progressive MS are using the same kind of clinical services to those with 269 
RRMS.   270 
Similar proportions of participants received multiple services (54%) or a single 271 
service (46%) for their MS.  Those who received a single service for their MS had a 272 
better quality of life and lower psychological and physical impact of MS compared to 273 
those who received multiple services which may be a reflection of clinical need and 274 
in turn likely to be associated with disability level.   275 
There was no association between rural or urban dwelling and access to an MS 276 
Specialist or receiving a regular review.  Previous research by Lonergan et al. in the 277 
Republic of Ireland found a lack of access to services was associated with rural 278 
dwelling.25 These researchers however surveyed people with all types of MS, and in 279 
addition 37% of the population live rurally in the Republic of Ireland, compared to 280 
18% in the UK26 which may explain the differences in results reported. Furthermore, 281 
the lack of association between rural and urban living and access to an MS 282 
Specialist may be due to the definition of access used in this study being the 283 
opportunity to see a clinician regardless of personal and organisational barriers.   284 
Five percent of this sample was currently taking DMT and 23% had been prescribed 285 
them previously. This result is lower than previously reported by the MS Society 286 
which found 56% of all people with all types of MS in UK were taking DMT.10 This 287 
difference is expected as prescribing guidelines state that DMT are not effective in 288 
progressive forms of MS when relapses are not present 27 and that those on DMT 289 
currently may have been prescribed them whilst in the relapsing remitting phase of 290 
MS.  The five percent of participants still taking DMT does however, contribute 291 
further to the importance of a regular clinical review as there are potentially a large 292 
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number of people with MS inappropriately taking these drugs in the UK.  293 
Furthermore those taking DMT had a better quality of life compared to those who 294 
were not.  Those who had previously taken DMT however, had a poorer quality of life 295 
and a greater physical and psychological impact of MS compared to those who had 296 
never taken them.  These differences were however small and may be an indication 297 
of the stage of disease, as those who are no longer taking DMT may have more 298 
advanced disease, and transitioned into the secondary progressive phase for which  299 
DMT are no longer appropriate. 300 
Study Limitations 301 
The open and voluntary nature of the UK MS Register and online surveys leave the 302 
sample open to bias to the motivated and those with a vested interest.  In addition 303 
those who are more severely disabled and find it difficult to access services may not 304 
be on the register. The diagnosis and type of MS was self-reported, however in 305 
future the UK MS Register will be linked with clinical data from the NHS. The concept 306 
of access is multi-faceted and even though the definition of access as the 307 
opportunity to see a clinician was implied by the questions asked, it was not implicitly 308 
defined which may have affected responses.   For example if they felt that even their 309 
clinician was not available due to a long waiting list they may have selected that they 310 
did not have access.  A programming error lead to the responses regarding access 311 
and use of MS Doctor and MS Nurse being combined and were thus combined in the 312 
results. There were no geographical data available for participants in Northern 313 
Ireland which limited the analysis comparing participants living in a rural and urban 314 
setting.  Participants may have encountered problems with memory recall when 315 
asked regarding the regularity of review. This may have resulted in errors in 316 
reporting with those who more recently received their review being more likely to 317 
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report it.  Lastly due to the conditions of ethical approval it was not possible to 318 
examine the demographics of those who did not respond to the survey to determine 319 
if they were typical of those registrants of the UK MS Register with progressive MS. 320 
 321 
Conclusion 322 
This was the first survey of its kind examining access and use of clinical services by 323 
people with progressive MS in the UK, and had the largest sample of people with 324 
progressive MS to date. Access to an MS Specialist was high and use of clinical 325 
services for participant’s MS was also high. However a gap in service provision, 326 
which is breaching national guidelines, was found in relation to regular reviews and 327 
health care providers in the UK should address this. Furthermore investigation 328 
should also establish the effectiveness and patient satisfaction of services used. 329 
Disclosures/ Conflict of interest 330 
The Authors declare there is no conflict of interest. 331 
Funding/Support 332 
This project was supported by the Bevan Scholarship, NHS Ayrshire & Arran.  333 
17 
 
Reference list 334 
 335 
1. Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O'Riordan J. Incidence and 336 
prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General 337 
Practice Research Database. J Neurol Neurosurg Psychiatry. 2014;85(1):76-84. 338 
2. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6(10):903-339 
912. 340 
3. Montalban X, Hemmer B, Rammohan K, et al. Efficacy and Safety of Ocrelizumab in Primary 341 
Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled 342 
ORATORIO Study (S49.001). Neurology. 2015;86(16):S49.001. 343 
4. Holland NJ, Schneider DM, Rapp R, Kalb RC. Meeting the needs of people with primary 344 
progressive multiple sclerosis, their families, and the health-care community. International 345 
journal of MS care. 2011;13(2):65-74. 346 
5. Fox RJ, Thompson A, Baker D, et al. Setting a research agenda for progressive multiple 347 
sclerosis: the International Collaborative on Progressive MS. Mult Scler. 2012;18(11):1534-348 
1540. 349 
6. Campbell E, Coulter EH, Mattison PG, Miller L, McFadyen A, Paul L. Physiotherapy 350 
rehabilitation for people with progressive Multiple Sclerosis: a systematic review. Arch Phys 351 
Med Rehabil. 2015;97(1):141-151.e143. 352 
7. NICE. Multiple sclerosis. Management of multiple sclerosis in primary and secondary care. 353 
Clinical guideline 186. London: National Institure for Health and Care Excellence; 2014. 354 
8. Healthcare Improvement Scotland. Clinical Standards ~ October 2009 Neurological Health 355 
Services. Edinburgh2009. 356 
9. Mynors G, Suppiah J, Bowen A. Evidence for MS Specialist Services: findings from the GEMSS 357 
MS specialist nurse evaluation project. Multiple Sclerosis Trust;2015. 358 
10. MS Society. My MS My Needs 2016: access to treatment and health care. Technical report. 359 
MS Society;2016. 360 
11. Edmonds P, Vivat B, Burman R, Silber E, Higginson IJ. 'Fighting for everything': service 361 
experiences of people severely affected by multiple sclerosis. Mult Scler. 2007;13(5):660-667. 362 
12. MacLurg K, Reilly P, Hawkins S, Gray O, Evason E, Whittington D. A primary care-based needs 363 
assessment of people with multiple sclerosis. Br J Gen Pract. 2005;55(514):378-383. 364 
13. Markwick R, Singleton C, Conduit J. The perceptions of people with multiple sclerosis about 365 
the NHS provision of physiotherapy services. Disabil Rehabil. 2014;36(2):131-135. 366 
14. Ford DV, Jones KH, Middleton RM, et al. The feasibility of collecting information from people 367 
with Multiple Sclerosis for the UK MS Register via a web portal: characterising a cohort of 368 
people with MS. BMC Med Inform Decis Mak. 2012;12:73. 369 
15. Jones KH, Ford DV, Jones C, et al. A case study of the Secure Anonymous Information Linkage 370 
(SAIL) Gateway: a privacy-protecting remote access system for health-related research and 371 
evaluation. Journal of biomedical informatics. 2014;50:196-204. 372 
16. Campbell E, Coulter EH, Mattison PG, Miller L, McFadyen A, Paul L. Access, delivery and 373 
perceived efficacy of physiotherapy and use of complementary and alternative therapies by 374 
people with progressive multiple sclerosis in the United Kingdom:  an online survey. Multiple 375 
Sclerosis and Related Disorders. 2017;In press. 376 
17. Levesque JF, Harris MF, Russell G. Patient-centred access to health care: conceptualising 377 
access at the interface of health systems and populations. Int J Equity Health. 2013;12:18. 378 
18. Office for National Statistics. 2011 rural/urban classification. 2016; 379 
https://www.ons.gov.uk/methodology/geography/geographicalproducts/ruralurbanclassific380 
ations/2011ruralurbanclassification. Accessed January 2016, 2016. 381 
18 
 
19. Scottish Office for National Statistics. 2011 Census Indexes. 2016; 382 
http://www.nrscotland.gov.uk/statistics-and-data/geography/our-products/census-383 
datasets/2011-census/2011-indexes. Accessed January 2016, 2016. 384 
20. Department for Communities and Local Govenment. Urban and rural area definitions: a user 385 
guide. 2006; 386 
http://webarchive.nationalarchives.gov.uk/20120919132719/http:/www.communities.gov.u387 
k/documents/planningandbuilding/pdf/156303.pdf, 2016. 388 
21. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. 389 
Health Policy. 1990;16(3):199-208. 390 
22. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale 391 
(MSIS-29): a new patient-based outcome measure. Brain. 2001;124(Pt 5):962-973. 392 
23. Devlin N, Shah K, Feng Y, Mulhern B, Van Hout B. Valuing Health-Related Quality of Life: An 393 
EQ-5D-5L Value Set for England. Online: Office of Health Economics;2016. 394 
24. Kersten P, McLellan DL, Gross-Paju K, et al. A questionnaire assessment of unmet needs for 395 
rehabilitation services and resources for people with multiple sclerosis: results of a pilot 396 
survey in five European countries. Needs Task group of MARCH (Multiple Sclerosis and 397 
Rehabilitation, Care and Health Services Research in Europe). Clin Rehabil. 2000;14(1):42-49. 398 
25. Lonergan R, Kinsella K, Fitzpatrick P, et al. Unmet needs of multiple sclerosis patients in the 399 
community. Mult Scler Relat Disord. 2015;4(2):144-150. 400 
26. World Data Bank. 2016; http://wdi.worldbank.org/table/3.1. Accessed June, 2016. 401 
27. Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) 402 
guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 403 
2015;15(4):273-279. 404 
 405 
  406 
19 
 












Age (years) 59 (8) 60 (8) 58 (9) p<0.001
a 




   
  Female  824 246 578 p<0.001
b 
  Male  474 240 234 - 
Country [where known]    
  Scotland  130 57 73 p=0.343 
  England  1030 372 658 - 
  Wales  104 40 64 - 
  N. Ireland  21 9 12 - 
EQ-5D-3L 
index 








55.97 (12.64) 54.46 (13.27) 56.88 (12.12) p=0.002
a 
Abbreviations: n: number of responses; TSD: Time Since Diagnosis; EQ-5D-3L: EQ-408 
5D-3L Health Questionnaire; MSIS-29 psych: Multiple Sclerosis Impact Scale-29 409 
psychological sub-scale; MSIS-29 phys: Multiple Sclerosis Impact Scale-29 physical 410 
sub-scale 411 
Figures where applicable are mean and SD.  Not every participant had demographic 412 
data available, for example country of domicile. Mean time between survey 413 
completion and most recent EQ-5D-3L and MSIS-29 completions were 39 (120) and 414 
19 (111) days. 415 
aStatistically significant as calculated by Mann-Whitney tests.   416 
bStatistically significant as calculated by Chi-square test.   417 
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Table 2. Survey responses regarding a regular review for progressive MS.  419 
Question   Answer n % 
Are you offered a regular clinical 
review for your MS?  
Yes 917 74 
No  287 23 
(n=1243) Don’t know  39 3 
On average; how often is your  
review? 
Twice a year 57 6 
Once a year 505 55 
(n=912)  Less  frequently than once a year 341 37 
  Don’t know  9 1 
Who usually undertakes your  
review? 
MS Specialist Doctor/Neurologist 569 63 
GP 8 1 
(n=911) Nurse 248 27 
 
Physiotherapist 12 1 
 
Occupational therapist 6 1 
 
The person can vary 58 6 
 Other  10 1 
Where does your review normally 
take place?  
At home 43 5 
In a hospital or clinic 819 90 
(n=911) In a community centre 10 1 
 
GP surgery 20 2 
 Other  19 2 
Abbreviations: n: number of participants; GP: General Practitioner. 420 
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Table 3. Associations between access to an MS Specialist and MS type, past and 423 
present DMT use, rural or urban living and receiving a regular review. 424 
  n p 
Access to MS Specialist and PPMS or SPMS 1248 0.473 
Access to MS Specialist and past DMT use 1227a 0.371 
Access to MS Specialist and current DMT use 362a 0.175 
Access to MS Specialist and urban/rural dwelling 1201 1.000 
Access to MS Specialist and regular review 1233 <0.001 b 
Abbreviations: n: number of responses; PPMS: Primary Progressive Multiple 425 
Sclerosis; SPMS: Secondary Progressive Multiple Sclerosis; DMT: Disease 426 
Modifying Therapies. 427 
an is significantly higher than results of current and past DMT use reported in main 428 
text (88 and 303 respectively) as Chi-square test also includes the participants who 429 
answered no.  430 
bStatistically significant result from Chi-square test. 431 
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Table 4. Differences in EQ-5D-3L and MSIS-29 scores in those with and without 433 
access to a MS Specialist, regular review, receiving more than one MS service, and 434 
current and past DMT use. 435 
Access to MS 
specialist yes no 
 
 
n med n med p 
EQ-5D-3L index 1154 0.57 62 0.50 0.245 
MSIS-29 phys 1180 56.00 64 58.50 0.581 
MSIS-29 psych 1167 19.00 63 19.00 0.832 
Access to review  Yes no 
 
 
n med n med p 
EQ-5D-3L index 898 0.57 276 0.57 0.642 
MSIS-29 phys 914 56.00 286 58.00 0.187 
MSIS-29 psych 903 19.00 285 19.00 0.410 
Single/multiple 
services single multiple 
 
 
n med n med p 
EQ-5D-3L index 469 0.57 548 0.50 <0.001a 
MSIS-29 phys 478 55.00 563 59.00 <0.001a 
MSIS-29 psych 473 18.00 555 20.00 <0.001a 
 
yes no 
 Current DMT use n med n med p 
EQ-5D-3L index 87 0.57 346 0.50 0.016 a 
MSIS-29 phys 87 56.00 359 60.00 0.050 
MSIS-29 psych 85 20.00 357 20.00 0.960 
 
yes No 
 Past DMT Use n med n med p 
EQ-5D-3L index 296 0.50 912 0.57 <0.001a 
MSIS-29 phys 302 59.00 935 56.00 <0.001a 
MSIS-29 psych 299 20.00 925 19.00 0.006 a 
Abbreviations: n: number of responses; med: median; EQ-5D-3L: EQ-5D-3L Health 436 
Questionnaire; MSIS-29 psych: Multiple Sclerosis Impact Scale-29 psychological 437 
sub-scale; MSIS-29 phys: Multiple Sclerosis Impact Scale-29 physical sub-scale; 438 
DMT: Disease Modifying Therapies  439 
Not all participants had EQ-5D-3L or MSIS-29 data available.  This accounts for 440 
slight variation in n. 441 
aStatistically significant as calculated by Mann-Whitney tests.   442 
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Figure 1: Access to MS Specialists across the UK 444 
 445 
Figure 1. Access to MS Specialists by people with progressive MS within Scotland, 446 
Northern Ireland, Wales and the Strategic Health Authorities in England. 447 
 448 
 449 
Figure 2. Clinical services used for MS in the past three months. 450 
Figure 2. Clinical services used by participants for their MS in the prior three months. 451 
Abbreviations: MSDr/NS: MS Doctor or MS Nurse; GP: General Practitioner; Physio: 452 
Physiotherapist; OT: Occupational Therapist; Cont NS: Continence Nurse; NS oth: 453 
Nurse other; Dr oth: Doctor other; Orth: Orthotist; SW: Social Worker; Oth: other; 454 
Psych: Psychologist; SLT: Speech and Language Therapist; Diet: Dietician 455 
 456 
